ReviewFrontiers in immunology2022
Inflammation in Cerebral Venous Thrombosis.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Cerebral venous thrombosis in non-bacterial infections: a systematic review.BMC neurology · 2026Pooled it
- Inflammatory biomarkers in cerebral venous thrombosis versus ischemic stroke: a network meta-analysis.Frontiers in neurology · 2025Pooled it
- Engineering neurovascular thrombosis: Light-based bioprinting for patient-specific modeling and women's cerebrovascular health.Science advances · 2026Review
- Cerebral Venous Sinus Thrombosis Revealing ALK-Positive Anaplastic Large-Cell Lymphoma in a Patient with Inherited Thrombophilia and Concomitant Infection: Case Report and Narrative Review.Life (Basel, Switzerland) · 2026Article
- Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and systemic immune-inflammation index as predictors of venous thromboembolism in patients with diffuse large B-cell lymphoma.Thrombosis journal · 2026Article
- Cerebral Veins and Dural Sinuses Thrombosis: Data from a Monocentric Cohort Study of 55 Romanian Patients.Life (Basel, Switzerland) · 2026Article
- Systemic inflammatory markers predict mortality in autoimmune thyroiditis: threshold-driven risk stratification and prognostic insights from a nationwide cohort.Hormones (Athens, Greece) · 2026Article
- Cerebral Venous Thrombosis in Previously Healthy Patients with Cryptococcal Meningitis.The Journal of infectious diseases · 2026Article
- Comparative screening performance and multicenter validation of novel inflammatory biomarkers (NLR, SII, and CAR) for risk stratification of diabetic foot ulcer in patients with type 2 diabetes mellitus.Frontiers in medicine · 2026Article
- Association of SIRI and NLPR with post-operative pneumonia in middle-aged and elderly patients after hip fracture surgery.Frontiers in medicine · 2026Article
- Association of the systemic immune-inflammation index with consciousness disturbance in cerebral venous sinus thrombosis: a retrospective cohort study.Frontiers in immunology · 2026Article
- Predicting 3-month prognosis of cerebral venous thrombosis: a machine learning approach incorporating inflammatory markers.Frontiers in neurology · 2026Article
- Inflammatory markers and clinical outcomes in acute/subacute severe cerebral venous thrombosis: the role of glucocorticoid therapy.BMC neurology · 2025Article
- Triglyceride-glucose (TyG) index combined with C-reactive protein outperforms the TyG index alone in predicting stroke in arthritis patients: a nationwide prospective cohort study.Lipids in health and disease · 2025Article
- Autoimmune manifestations recorded after SARS-CoV-2 vaccination.Clinical and experimental vaccine research · 2025Article
- Predictive Value of Combined CRP and INR for Intracranial Hypertension in Cerebral Venous Thrombosis.Immunity, inflammation and disease · 2025Article
- Article
- Endovascular management of dural arteriovenous fistulae of the anterior condylar confluence.Journal of cerebrovascular and endovascular neurosurgery · 2025Article
- Immune-mediated blood-brain barrier disruption after ischemic stroke: mechanisms and therapeutic targets.Frontiers in immunology · 2025Review
- Escin Rescues Blood-brain Barrier and Inhibits NLRP3 Inflammasome-mediated Pyroptosis in Rats with Superior Sagital Sinus Thrombosis.International journal of medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral venous thrombosis (CVT) is a rare form of cerebrovascular disease that impairs people's wellbeing and quality of life. Inflammation is considered to play an important role in CVT initiation and progression. Several studies have reported the important role of leukocytes, proinflammatory cytokines, and adherence molecules in the CVT-related inflammatory process. Moreover, inflammatory factors exacerbate CVT-induced brain tissue injury leading to poor prognosis. Based on clinical observations, emerging evidence shows that peripheral blood inflammatory biomarkers-especially neutrophil-to-lymphocyte ratio (NLR) and lymphocyte count-are correlated with CVT [mean difference (MD) (95%CI), 0.74 (0.11, 1.38), p = 0.02 and -0.29 (-0.51, -0.06), p = 0.01, respectively]. Moreover, increased NLR and systemic immune-inflammation index (SII) portend poor patient outcomes. Evidence accumulated since the outbreak of coronavirus disease-19 (COVID-19) indicates that COVID-19 infection and COVID-19 vaccine can induce CVT through inflammatory reactions. Given the poor understanding of the association between inflammation and CVT, many conundrums remain unsolved. Further investigations are needed to elucidate the exact relationship between inflammation and CVT in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.